CJC-1295 research guide
Growth-hormone-releasing hormone analogue family
A nomenclature-first guide that separates CJC-1295 with DAC from shorter non-DAC material and maps the limited human and analytical evidence.
AUS Peptide Supply editorial team01 · Identity
What the name identifies
The label CJC-1295 is used inconsistently online. The long-acting drug-affinity-complex form studied in early human trials is not the same analytical entity as material commonly described as CJC-1295 without DAC or modified GRF (1-29). A useful record must state the exact sequence or molecular formula, expected mass and whether the DAC moiety is present.
02 · Evidence position
What the literature can support
Small early-phase human studies exist for the long-acting DAC form. They do not establish evidence for every product sold under the shortened CJC-1295 name. Because nomenclature ambiguity can defeat otherwise competent testing, identity definition is the first evidence checkpoint.
03 · Study-level map
Evidence and its limits
Which form was studied in humans?
Two randomised, placebo-controlled, ascending-dose studies evaluated a long-acting CJC-1295 analogue in healthy adults.
Limit: The sample was limited and the paper does not validate non-DAC material or commercial catalogue batches using the same family name.
Why does naming matter?
PubChem maintains separate molecular records that can be used to verify which entity a stated formula or mass describes.
Limit: A matching database entry is a reference point, not batch-specific proof.
What is the Australian context?
The TGA specifically identifies CJC-1295 in current unapproved-peptide guidance.
Limit: A research-use statement does not by itself determine whether importation, advertising or supply is lawful.
04 · Analytical context
Questions a batch record should answer
- 01Does the report explicitly identify DAC or non-DAC material rather than using only the umbrella name?
- 02Do expected molecular mass, formula and sequence agree with the named form?
- 03Are identity and purity supported by complementary methods rather than one ambiguous chromatogram label?
05 · Boundary conditions
What this record does not establish
- Evidence for the DAC form cannot be silently transferred to the non-DAC form.
- The common CAS reference is frequently applied inconsistently across vendor records.
- No performance, recovery or human-use conclusion is made here.
Sources checked
- 1.Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults
PubMed / Journal of Clinical Endocrinology & Metabolism · 2006 · Primary study
- 2.CJC-1295 compound record
NIH PubChem · 2026 · Chemical database
- 3.Understanding your responsibilities when supplying unapproved peptide products
Therapeutic Goods Administration · 2026 · Regulator